Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Teodora Radonic"'
Autor:
Asli Küçükosmanoglu, Carolien L. van derBorden, Lisanne E. A. deBoer, Roel Verhaak, David Noske, Tom Wurdinger, Teodora Radonic, Bart A. Westerman
Publikováno v:
Molecular Oncology, Vol 18, Iss 10, Pp 2407-2422 (2024)
Genetic heterogeneity in tumors can show a remarkable selectivity when two or more independent genetic events occur in the same gene. This phenomenon, called composite mutation, points toward a selective pressure, which frequently causes therapy resi
Externí odkaz:
https://doaj.org/article/2f535455fe3d438d87cea860c9cbc6cf
Autor:
Franziska Böttger, Teodora Radonic, Idris Bahce, Kim Monkhorst, Sander R. Piersma, Thang V. Pham, Anne‐Marie C. Dingemans, Lisa M. Hillen, Mariacarmela Santarpia, Elisa Giovannetti, Egbert F. Smit, Sjaak A. Burgers, Connie R. Jimenez
Publikováno v:
Molecular Oncology, Vol 18, Iss 6, Pp 1417-1436 (2024)
The majority of patients with resected stage II‐IIIA non‐small cell lung cancer (NSCLC) are treated with platinum‐based adjuvant chemotherapy (ACT) in a one‐size‐fits‐all approach. However, a significant number of patients do not derive c
Externí odkaz:
https://doaj.org/article/59cc7532a44a481fb7f9c9573d143ffd
Autor:
Tanja D de Gruijl, Lilian J Meijboom, Teodora Radonic, Chris Dickhoff, Idris Bahce, Sayed M S Hashemi, Daniela E Oprea-Lager, Ezgi B Ulas, Suresh Senan, Famke L Schneiders, Joris Veltman, David J Heineman, Anne Vrijmoet, Ilias Houda, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Febe van Maldegem, Marieke F Fransen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Background In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borde
Externí odkaz:
https://doaj.org/article/f70d8187e5304db89a6c5551cdddd8e7
Autor:
Tanja D de Gruijl, Teodora Radonic, Marc C Huisman, Idris Bahce, Johanna E E Pouw, Sayed M S Hashemi, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Suresh Senan, C Willemien Menke-van der Houven van Oordt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy following concur
Externí odkaz:
https://doaj.org/article/4b3a18abdb6f4a34986c4c57af3d9db7
Autor:
Benoit Lechartier, Athénaïs Boucly, Sabina Solinas, Deepa Gopalan, Peter Dorfmüller, Teodora Radonic, Olivier Sitbon, David Montani
Publikováno v:
European Respiratory Review, Vol 33, Iss 171 (2024)
Pulmonary veno-occlusive disease (PVOD), also known as “pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement”, is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement
Externí odkaz:
https://doaj.org/article/26126b5e7c2d47f48fd0ba3420c91a76
Autor:
Illaa Smesseim, Robert A. vanBoerdonk, Chris Dickhoff, David J. Heineman, Max R. Dahele, Teodora Radonic, Idris Bahce, Simone P. Rauh, Emile F. I. Comans, Hans (J. M. A.) Daniels
Publikováno v:
Thoracic Cancer, Vol 14, Iss 9, Pp 840-847 (2023)
Abstract Introduction Pre‐invasive squamous lesions of the central airways can progress into invasive lung cancers. Identifying these high‐risk patients could enable detection of invasive lung cancers at an early stage. In this study, we investig
Externí odkaz:
https://doaj.org/article/e71e7ab1bfc648928cada2fe02e71578
Autor:
Ezgi B. Ulas, BSc, Sayed M.S. Hashemi, MD, Ilias Houda, MD, Adem Kaynak, MSc, Joris D. Veltman, MD, PhD, Marieke F. Fransen, PhD, Teodora Radonic, MD, PhD, Idris Bahce, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100532- (2023)
Introduction: In advanced-stage NSCLC, tumor proportion score (TPS) is typically used to predict the efficacy of immune checkpoint inhibitors (ICIs). Nevertheless, in other cancer types, the combined positive score (CPS), which covers programmed deat
Externí odkaz:
https://doaj.org/article/e19f82a0ac474b54adcefd75bbe9d1ac
Autor:
Chris Dickhoff, Suresh Senan, Famke L. Schneiders, Joris Veltman, Sayed Hashemi, Johannes M. A. Daniels, Marieke Fransen, David J. Heineman, Teodora Radonic, Peter M. van de Ven, Imke H. Bartelink, Lilian J. Meijboom, Juan J. Garcia-Vallejo, Daniela E. Oprea-Lager, Tanja D. de Gruijl, Idris Bahce
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background The likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected
Externí odkaz:
https://doaj.org/article/b810006f73e5465ca6860f5c7acd4a6c
Autor:
Tanja de Gruijl, Teodora Radonic, Chris Dickhoff, Marieke Fransen, Famke Schneiders, Vinitha Kandiah, Idris Bahce
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/fc91662ef29942c99972f61ea8a47223
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-6 (2019)
Abstract Background Pulmonary carcinoids are included in the group of neuroendocrine tumors (NET) and derive from pulmonary neuroendocrine cells. The incidence of these tumors is increasing, but disease awareness remains low among clinicians. The syn
Externí odkaz:
https://doaj.org/article/fae882b7884c42e1a9d17574afeb4d57